Observational studyBMC musculoskeletal disorders2026
Comparison of bone mineral density between the tumour side and the healthy side in patients with malignant tumours of the long bones of the lower extremities: a prospective study.
Observational study in BMC musculoskeletal disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study aimed to compare bone mineral density (BMD) between the tumour-affected and contralateral healthy sides in patients with primary or metastatic malignant tumours of the long bones of the lower extremities, and to evaluate the clinical relevance of these differences regarding fracture risk.
methodsA single-centre, prospective observational study was conducted at Uludağ University between May 2021 and May 2022. Forty-two patients (22 with primary and 20 with metastatic malignant tumours of the femur or tibia) were included. Bilateral BMD measurements were obtained using dual-energy X-ray absorptiometry (DEXA). Demographic data, biochemical parameters (vitamin D, parathyroid hormone [PTH], calcium), and tumour characteristics were recorded. Inter-side BMD differences were analysed, and correlations with clinical and biochemical factors were assessed using Spearman correlation and multiple linear regression analyses.
resultsPatients with metastatic tumours were significantly older (median 67.5 years) than those with primary tumours (median 46 years, p = 0.002). Lumbar and tumour-side DEXA values were significantly lower in the metastasis group (p = 0.035). Intra-group analyses revealed that BMD on the tumour side was significantly reduced compared with the contralateral side in both groups (p < 0.001), indicating a marked local bone loss. Correlation analysis showed a negative association between age and DEXA scores in metastatic cases, while BMI correlated positively with lumbar BMD. PTH level emerged as a significant independent predictor of BMD across all regression models (p < 0.01).
conclusionMalignant tumours of the lower-extremity long bones lead to a significant reduction in local BMD, independent of systemic bone metabolism. The results highlight the importance of bilateral DEXA evaluation to differentiate local from systemic bone loss and to better predict fracture risk. Routine assessment of PTH may further assist in monitoring bone health in oncologic patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.